Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (342)	5/13/1999 6:48:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 579

addressing the Pfizer mess...... In the Reuter's story, it said "Pfizer has asked the court for a jury trial". So....... If Pfizer is so certain that there is prior art, why do they want a jury? If Pfizer is so certain that there is prior art, why are they suing Sibia instead of simply buying KDUS? If they're correct, they'd be getting a $60M company for $20M and dealing with the SIBI threat.

To: LLCF who wrote (342)	5/13/1999 7:52:00 PM
From: scaram(o)uche	Respond to of 579

looking at today's release...... "We are surprised that Pfizer has chosen this means of communicating its lack of interest in a license," stated Stephen F. Keane A great straight line. If Pfizer can't come up with rationale to invalidate the patent, I hope that the court hits them really, really, really, really hard. OTOH, while I believe in broad claims and protection, I'll tip my hat to PFE if they can find a good argument. "We are currently in negotiations with a number of other companies and expect that the value of this patented technology will increase as licensed by additional biotechnology and pharmaceutical companies." The Reuter's article says that SIBI is asking for 0.5%. Together with maintenance payments, that's $3 million/year for a drug selling at $500 million. I'll therefore project license revenue for '629 and '128 at about $6-$10 million/year through 2005, and increasing to $50 million for 2010. I was hoping that the Bristol-Myers Squibb and SmithKline Beecham deals had been signed at 1%, but now I guess we'll need to wait for Pfizer to lose to see those sorts of numbers. ;-) Arrogance aside, if anyone has a handle on any prior art, please post away!!